Last $183.32 USD
Change Today 0.00 / 0.00%
Volume 0.0
ALXN On Other Exchanges
As of 8:10 PM 01/23/15 All times are local (Market data is delayed by at least 15 minutes).

alexion pharmaceuticals inc (ALXN) Snapshot

Previous Close
Day High
Day Low
52 Week High
12/3/14 - $203.30
52 Week Low
01/27/14 - $126.76
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

alexion pharmaceuticals inc (ALXN) Related Businessweek News

View More BusinessWeek News

alexion pharmaceuticals inc (ALXN) Details

Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. It offers Soliris (eculizumab), a therapeutic product to treat paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and atypical hemolytic uremic syndrome (aHUS), a genetic disease. The company also conducts Phase IV clinical trials on Soliris for its usage for the treatment of PNH registry, and aHUS for pediatric and adult; and various Phase II clinical trials for its usage for the treatment of PNH pediatric trial, presensitized renal transplant, delayed kidney transplant graft function, hemolytic uremic syndrome, neuromyelitis optica, myasthenia gravis, and cold agglutinin disease. In addition, it develops Asfotase alfa that is under Phase II clinical trial for the treatment of metabolic disorders, including hypophosphatasia; ALXN 1102/1103, which is in Phase I trial for PNH; ALXN 1007, a novel humanized antibody for treating inflammatory disorders; and cPMP that is in Phase I trial for treating metabolic disorders. The company primarily serves distributors, pharmacies, hospitals, hospital buying groups, and other health care providers, as well as governments and government agencies. Alexion Pharmaceuticals, Inc. has a strategic agreement with Moderna Therapeutics, Inc. for the development of messenger RNA therapeutics to treat rare diseases. The company sells its products primarily in the United States, Europe, and the Asia Pacific. Alexion Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Cheshire, Connecticut.

1,774 Employees
Last Reported Date: 02/10/14
Founded in 1992

alexion pharmaceuticals inc (ALXN) Top Compensated Officers

Co-Founder, Chairman of the Board and Chief E...
Total Annual Compensation: $1.2M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $615.0K
Global Head of Research & Development and Exe...
Total Annual Compensation: $547.0K
Chief Strategy & Portfolio Officer and Senior...
Total Annual Compensation: $325.0K
Chief Operating Officer and Director
Total Annual Compensation: $610.0K
Compensation as of Fiscal Year 2013.

alexion pharmaceuticals inc (ALXN) Key Developments

Alexion Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2014

Alexion Pharmaceuticals, Inc. provided earnings guidance for the year 2014. The company announced that financial guidance for 2014 remains unchanged with revenue growing at 38% and non-GAAP EPS growing at 56%. And that excludes $88 million in prior year sales in France.

Alexion Pharmaceuticals, Inc. Reports Results from its Randomized, Open-Label, Multicenter Phase 2 Clinical Trial

Alexion Pharmaceuticals, Inc. reported results from its randomized, open-label, multicenter Phase 2 clinical trial to determine the safety and efficacy of eculizumab in the prevention of antibody mediated rejection (AMR) in living-donor kidney transplant recipients requiring desensitization. The primary composite endpoint, defined as the occurrence of biopsy-proven AMR, graft loss, patient death, or loss to follow-up at Week 9 post-transplant, did not reach statistical significance. While the primary composite endpoint rate in the eculizumab arm was as expected from earlier studies with eculizumab, the rate in the control arm was lower than was expected, based on natural history studies reported in the literature. Although eculizumab performed in line with the results reported from prior eculizumab studies, which showed similarly low AMR rates in high-risk patient populations. This Phase 2 trial enrolled 102 patients receiving kidney transplants from living donors, all of whom were at risk of AMR, based on elevated levels of donor-specific antibodies. After screening, patients were randomized into two groups of 51 patients each, with one group receiving eculizumab, and a control group receiving the anti-rejection standard of care specified by the institution in which each patient's transplant took place. Patients in the standard of care control arm were eligible to receive eculizumab treatment for presumed AMR. Data were collected during the nine-week treatment period for the primary composite endpoint, with additional safety and efficacy endpoints measured through 12 months post-transplant. In the analysis of the 9-week data, for the primary composite endpoint, the rate was 9.8% in the eculizumab arm and 15.7% in the control arm (P=0.554). No safety signal has been reported to the Company by the independent data monitoring committee. The company expects that the data from the study will be presented at a future medical meeting.

Alexion Pharmaceuticals, Inc. Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-12-2015 10:30 AM

Alexion Pharmaceuticals, Inc. Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-12-2015 10:30 AM. Venue: Westin St. Francis Hotel, San Francisco, California, United States. Speakers: David L. Hallal, Chief Operating Officer and Director, Leonard Bell, Co-Founder, Chairman of the Board and Chief Executive Officer.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ALXN:US $183.32 USD 0.00

ALXN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Croda International PLC 2,746 GBp +6.00
Dr Reddy's Laboratories Ltd 3,350 INR 0.00
Regeneron Pharmaceuticals Inc $420.21 USD 0.00
Sigma-Aldrich Corp $137.69 USD 0.00
Symrise AG €57.06 EUR +1.00
View Industry Companies

Industry Analysis


Industry Average

Valuation ALXN Industry Range
Price/Earnings 76.4x
Price/Sales 17.5x
Price/Book 11.6x
Price/Cash Flow 75.0x
TEV/Sales 16.6x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ALEXION PHARMACEUTICALS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at